# Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/TWST/twist-bioscience-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: TWST
Company: Twist Bioscience Corporation
Source: Twist Bioscience Corporation
Published: 2026-05-05 12:00 EST
Original Source URL: https://investors.twistbioscience.com
## Summary

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 5, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of

## Article Body
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 5, 2026-- As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of
## Recent Company News
- 2026-05-27 12:00 EST — [Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/TWST/twist-bioscience-to-present-at-william-blair-46th-annual-growth-stock-conference) — Source: Twist Bioscience Corporation
- 2026-05-05 12:00 EST — [Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TWST/twist-bioscience-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Twist Bioscience Corporation
- 2026-05-04 11:20 EST — [Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences](https://biopharmsignal.com/news/TWST/twist-bioscience-expands-clonal-genes-offering-to-include-long-and-complex-sequences) — Source: Twist Bioscience Corporation
- 2026-05-04 11:15 EST — [Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results](https://biopharmsignal.com/news/TWST/twist-bioscience-announces-fiscal-2026-second-quarter-financial-results) — Source: Twist Bioscience Corporation
- 2026-04-21 12:00 EST — [Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026](https://biopharmsignal.com/news/TWST/twist-bioscience-to-report-fiscal-2026-second-quarter-financial-results-on-monday-may-4-2026) — Source: Twist Bioscience Corporation
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)